| Shattuck Labs Announces Addition to Russell 2000® and Russell 3000® Indexes | 07/01 06:00 | globenewswire.com |
| Shattuck (STTK) Announces Positive Interim Data on Cancer Drug | 06/14 14:31 | zacks.com |
| Shattuck Labs Announces Updated Positive Interim Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 in Combination with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients | 06/14 06:00 | globenewswire.com |
| Shattuck Labs Announces Orphan Drug Designation Granted by the U.S. Food and Drug Administration (FDA) for SL-172154 for the Treatment of Acute Myeloid Leukemia (AML) | 06/10 07:30 | globenewswire.com |
| Shattuck Labs to Host Investor Call and Webcast on Additional Interim Data Presented at the European Hematology Association (EHA) 2024 Congress from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients | 06/06 07:30 | globenewswire.com |
| After Plunging -19.89% in 4 Weeks, Here's Why the Trend Might Reverse for Shattuck Labs (STTK) | 05/21 10:36 | zacks.com |
| Shattuck Labs to Present Additional Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients at the European Hematology Association (EHA) 2024 Congress | 05/14 16:15 | globenewswire.com |
| What Makes Shattuck Labs (STTK) a New Buy Stock | 05/07 13:01 | zacks.com |
| Does Shattuck Labs (STTK) Have the Potential to Rally 34.17% as Wall Street Analysts Expect? | 05/07 10:56 | zacks.com |
| Shattuck Labs, Inc. (STTK) Reports Q1 Loss, Tops Revenue Estimates | 05/02 09:31 | zacks.com |